Cannabis Lab Shopping: The THC Potency Inflation Crisis Plaguing Legal Weed

There is a dirty secret in legal cannabis that most consumers never think about, and that many industry insiders would rather not discuss publicly. The THC percentage printed on your dispensary product's label may be significantly inflated — and the system that is supposed to prevent that has been compromised by a practice known as lab shopping.

The numbers are staggering. According to regulatory analyses across multiple states, 48 percent of licensed cannabis products deviate by 20 percent or more from their labeled THC content. That means nearly half the products on legal dispensary shelves are not what they claim to be. In some cases, the actual THC content is dramatically lower than advertised. In others, the discrepancy is so large that it amounts to consumer fraud.

The problem is not new, but it has reached a critical inflection point in 2026 as multiple states move simultaneously to crack down on testing manipulation. The question is whether the proposed solutions can fix a market failure that has become deeply embedded in the economics of legal cannabis.

What Is Lab Shopping?

Lab shopping is the practice of submitting cannabis samples to multiple testing laboratories and then using the highest result for product labeling. A grower might send identical samples from the same harvest to three or four different labs. If Lab A reports 22 percent THC, Lab B reports 26 percent, and Lab C reports 29 percent, the grower puts "29% THC" on the package.

The practice is possible because cannabis testing is not as precise as consumers might assume. Results for identical samples can vary by 15 to 30 percent between laboratories, depending on equipment calibration, testing methodology, sample preparation techniques, and even the specific part of the plant that was tested. A bud from the top of the plant exposed to the most light may test differently from a bud lower on the same stem.

That variability is a legitimate scientific challenge. But lab shopping weaponizes it, transforming what should be a quality assurance process into a marketing exercise. The lab that consistently produces the highest numbers attracts the most business, creating a perverse incentive structure where accuracy is punished and inflation is rewarded.

Why Higher Numbers Win

The entire lab shopping ecosystem exists because consumers have been conditioned to believe that higher THC percentages mean better cannabis. Walk into any dispensary and watch how people shop. A significant number of customers scan the THC percentages before reading strain names, looking at terpene profiles, or asking about effects.

This consumer behavior creates enormous commercial pressure. A product labeled at 30 percent THC will outsell an otherwise identical product labeled at 22 percent, even if the 22 percent product is actually more potent, better grown, and more accurately tested. Cultivators who refuse to lab shop — who accept honest test results even when they are lower — lose market share to competitors whose products carry inflated numbers.

The result is a race to the top of the THC scale that has produced absurd outcomes. Average reported THC levels on dispensary shelves have climbed steadily over the past several years, with flower routinely labeled at 28, 30, or even 35 percent THC. Many cannabis scientists and experienced cultivators will tell you privately that flower reliably testing above 30 percent THC is exceptionally rare, yet it has become commonplace on dispensary labels.

The Labs Caught in the Middle

Testing laboratories operate in a market where their customers — the cultivators and manufacturers — choose which lab to use. A lab that consistently returns accurate but lower results will lose clients to competitors who produce more favorable numbers. Labs that refuse to play the inflation game risk going out of business.

This creates what economists call a race to the bottom in quality. Labs that prioritize accuracy are financially penalized, while labs that are — to put it generously — more flexible in their methodologies are rewarded with increased business.

Some laboratories have responded by tweaking their methods within technically permissible bounds to produce higher results. Others have been caught engaging in outright fraud, fabricating results that bear no relationship to the actual cannabinoid content of the samples they received.

The fundamental problem is one of incentive alignment. As long as labs are paid by the companies whose products they are testing, and those companies can freely switch between labs based on results, the system will reward inflation over accuracy.

State-by-State Crackdowns

Multiple states have recognized the severity of the problem and are moving to address it through regulatory reform. The approaches vary, but several common themes have emerged.

Colorado: Senate Bill 161

Colorado, one of the oldest legal cannabis markets, is pursuing comprehensive reform through Senate Bill 161. The legislation proposes several major changes to how cannabis testing is regulated.

First, it would shift oversight of testing laboratories from the Marijuana Enforcement Division (MED) to the Colorado Department of Public Health and Environment (CDPHE). The rationale is that public health regulators bring a different perspective and set of priorities than enforcement-focused agencies, and are better equipped to evaluate laboratory science.

Second, SB 161 would establish a secret shopper testing program. Under this model, regulators would purchase products from dispensary shelves and submit them for independent testing, then compare the results against what is printed on the label. Products that deviate significantly would trigger enforcement action against both the manufacturer and the lab that produced the original inflated results.

Third, and perhaps most provocatively, the bill would tie sales tax rates to THC potency. Higher-potency products would be taxed at higher rates, creating a financial incentive for companies to be accurate about their THC content rather than inflating it. If a company claims 30 percent THC, it pays taxes on 30 percent THC — whether or not the product actually contains that much.

Massachusetts: Secret Shoppers and 300 Percent Inflation

Massachusetts has taken a particularly aggressive approach after state regulators discovered that some products were labeled with THC levels inflated by as much as 300 percent compared to independent testing results. A product labeled at 30 percent THC that independently tests at 7.5 percent is not a minor calibration error — it is a fundamental breakdown of consumer protection.

The state has launched its own secret shopper program, purchasing products from dispensaries and submitting them to independent laboratories for verification. Products that fail these spot checks face recall, and the laboratories that produced the original results face investigation and potential loss of their state licenses.

Oregon's Enforcement Actions

Oregon has been cracking down on testing irregularities through its existing regulatory framework, conducting audits of laboratory practices and taking enforcement action against labs that produce consistently anomalous results. The state has suspended or revoked licenses for laboratories found to be engaging in inflated testing.

ISO 17025: The Accreditation Solution

One of the most promising structural reforms is the push toward mandatory ISO 17025 accreditation for all cannabis testing laboratories. ISO 17025 is an international standard that specifies the general requirements for the competence of testing and calibration laboratories. It is the same standard applied to forensic laboratories, environmental testing facilities, and pharmaceutical quality control labs.

ISO 17025 accreditation requires laboratories to demonstrate technical competence, operate a documented quality management system, conduct regular proficiency testing, maintain traceable calibration of all instruments, and submit to regular external audits. It also requires that labs participate in inter-laboratory comparison programs, where multiple labs test the same blind samples and compare results.

For cannabis testing, mandatory ISO 17025 accreditation would address several of the root causes of potency inflation. It would standardize testing methods across labs, reduce the inter-lab variability that lab shopping exploits, create accountability through external auditing, and establish a minimum competence threshold that would push the least reliable labs out of the market.

Several states are now moving toward requiring ISO 17025 accreditation as a condition of licensure. The challenge is implementation timelines and costs. Achieving accreditation is a multi-year, multi-hundred-thousand-dollar process that smaller labs may struggle to afford. States need to balance the urgency of reform with the practical reality of not eliminating so many labs that the remaining ones cannot handle testing volume.

What Consumers Should Know

If you are a cannabis consumer who has been choosing products based primarily on THC percentage, the lab shopping crisis should give you pause. Here is what the data actually tells you about what you are buying.

THC Percentage Is Not a Quality Indicator

Higher THC does not mean better cannabis. This is perhaps the single most important piece of consumer education the cannabis industry has failed to deliver. The experience of consuming cannabis is shaped by a complex interaction of cannabinoids, terpenes, flavonoids, and other plant compounds. Two products with identical THC percentages can produce dramatically different effects depending on their full chemical profile.

The analogy to alcohol is instructive. A fine wine at 13 percent alcohol and a bottom-shelf vodka at 40 percent alcohol are both intoxicating, but no serious person would argue that the vodka is "better" because it has a higher alcohol percentage. Cannabis quality is similarly multidimensional.

The Numbers May Be Wrong

Given that nearly half of tested products deviate 20 percent or more from their labels, you should treat THC percentages as approximate rather than precise. A product labeled at 28 percent THC might actually contain 22 percent — or it might contain 33 percent. Either way, the label is not providing the reliable information you think it is.

What to Look for Instead

Terpene profiles, if available, provide more useful information about how a product is likely to make you feel. The growing conditions, curing process, and overall craftsmanship of the cultivation matter far more than a single potency number. If your dispensary has knowledgeable staff, ask about the full cannabinoid and terpene profile rather than just the THC percentage.

The Path Forward

The cannabis testing crisis is ultimately a problem of market structure, and it will require structural solutions. Secret shopper programs provide accountability. ISO 17025 accreditation establishes competence standards. Separating who pays for testing from who benefits from the results would address the fundamental incentive misalignment.

Some advocates have proposed a model similar to food safety inspection, where the government — not the company being tested — selects the laboratory and pays for the testing, with costs recovered through licensing fees. This would eliminate lab shopping entirely by removing the cultivator's ability to choose their tester.

Others have suggested that all testing results, including multiple tests from different labs, should be publicly disclosed, so consumers can see the full range of results rather than just the cherry-picked highest number.

Whatever combination of reforms ultimately prevails, the status quo is clearly unsustainable. A legal cannabis market that cannot reliably tell consumers what is in the products they are buying is a market that undermines its own legitimacy — and hands a rhetorical weapon to prohibition advocates who argue that the regulated market is no more trustworthy than the illicit one.

The good news is that regulators in multiple states now recognize the problem and are actively working to solve it. The bad news is that the problem has been allowed to fester for years, and undoing the culture of potency inflation will take sustained effort, significant investment, and a fundamental shift in how consumers evaluate cannabis quality.